{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:37:02Z","timestamp":1770745022135,"version":"3.49.0"},"reference-count":42,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2013,9,24]],"date-time":"2013-09-24T00:00:00Z","timestamp":1379980800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0075269","type":"journal-article","created":{"date-parts":[[2013,9,25]],"date-time":"2013-09-25T01:45:11Z","timestamp":1380073511000},"page":"e75269","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":30,"title":["Disrupting the Oncogenic Synergism between Nucleolin and Ras Results in Cell Growth Inhibition and Cell Death"],"prefix":"10.1371","volume":"8","author":[{"given":"Sari","family":"Schokoroy","sequence":"first","affiliation":[]},{"given":"Dolly","family":"Juster","sequence":"additional","affiliation":[]},{"given":"Yoel","family":"Kloog","sequence":"additional","affiliation":[]},{"given":"Ronit","family":"Pinkas-Kramarski","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2013,9,24]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"19925","DOI":"10.1074\/jbc.273.32.19925","article-title":"Increasing complexity of the Ras signaling pathway","volume":"273","author":"AB Vojtek","year":"1998","journal-title":"J Biol Chem"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0959-437X(98)80061-0","article-title":"Ras signalling and apoptosis","volume":"8","author":"J Downward","year":"1998","journal-title":"Curr Opin Genet Dev"},{"key":"ref3","first-page":"181","article-title":"Epidermal growth factor receptor and other oncogenes as prognostic markers","author":"AL Harris","year":"1992"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/300149a0","article-title":"A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene","volume":"300","author":"EP Reddy","year":"1982","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/300143a0","article-title":"Mechanism of activation of a human oncogene","volume":"300","author":"CJ Tabin","year":"1982","journal-title":"Nature"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nrc2960","article-title":"Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?","volume":"10","author":"D Vigil","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0925-4439(97)00077-X","article-title":"Stringent structural requirements for anti-Ras activity of S-prenyl analogues","volume":"1406","author":"Z Aharonson","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/bi972032d","article-title":"Dislodgment and accelerated degradation of Ras","volume":"37","author":"R Haklai","year":"1998","journal-title":"Biochemistry"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0167-4889(99)00144-5","article-title":"Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid","volume":"1452","author":"G Elad","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"22263","DOI":"10.1074\/jbc.270.38.22263","article-title":"Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid","volume":"270","author":"M Marom","year":"1995","journal-title":"J Biol Chem"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/pros.10336","article-title":"The novel Ras antagonist, farnesylthiosalicylate, suppresses growth of prostate cancer in vitro","volume":"58","author":"RA McPherson","year":"2004","journal-title":"Prostate"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.bcp.2006.05.007","article-title":"Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells","volume":"72","author":"S Erlich","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1038\/sj.onc.1202602","article-title":"A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice","volume":"18","author":"B Weisz","year":"1999","journal-title":"Oncogene"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/BF03402049","article-title":"A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells","volume":"6","author":"J Halaschek-Wiener","year":"2000","journal-title":"Mol Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1158\/1535-7163.MCT-06-0706","article-title":"Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid)","volume":"6","author":"A Zundelevich","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"26369","DOI":"10.1074\/jbc.274.37.26369","article-title":"Antiproliferative activity of G-rich oligonucleotides correlates with protein binding","volume":"274","author":"PJ Bates","year":"1999","journal-title":"J Biol Chem"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1096\/fasebj.13.14.1911","article-title":"Molecular dissection of nucleolin\u2019s role in growth and cell proliferation: new insights","volume":"13","author":"M Srivastava","year":"1999","journal-title":"FASEB J"},{"key":"ref18","article-title":"Conditional knockout of nucleolin in DT40 cells reveals the functional redundancy of its RNA binding domains","author":"S Storck","year":"2008","journal-title":"Biol Cell"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1471-2199-8-66","article-title":"Inactivation of nucleolin leads to nucleolar disruption, cell cycle arrest and defects in centrosome duplication","volume":"8","author":"I Ugrinova","year":"2007","journal-title":"BMC Mol Biol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1046\/j.1432-1033.2003.03929.x","article-title":"Surface nucleolin participates in both the binding and endocytosis of lactoferrin in target cells","volume":"271","author":"D Legrand","year":"2004","journal-title":"Eur J Biochem"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2007-07-104455","article-title":"Nuclear translocation of urokinase-type plasminogen activator","volume":"112","author":"V Stepanova","year":"2008","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e2518","DOI":"10.1371\/journal.pone.0002518","article-title":"Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin","volume":"3","author":"D Destouches","year":"2008","journal-title":"PLOS ONE"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"10491","DOI":"10.1158\/0008-5472.CAN-06-4206","article-title":"AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin","volume":"67","author":"Y Teng","year":"2007","journal-title":"Cancer Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"43221","DOI":"10.1074\/jbc.M104446200","article-title":"Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides","volume":"276","author":"X Xu","year":"2001","journal-title":"J Biol Chem"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"e2310","DOI":"10.1371\/journal.pone.0002310","article-title":"Identification of nucleolin as new ErbB receptors- interacting protein","volume":"3","author":"A Di Segni","year":"2008","journal-title":"PLOS ONE"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e6128","DOI":"10.1371\/journal.pone.0006128","article-title":"Structure-function analysis of nucleolin and ErbB receptors interactions","volume":"4","author":"K Farin","year":"2009","journal-title":"PLOS ONE"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1158\/0008-5472.CAN-10-2887","article-title":"Oncogenic synergism between ErbB1, nucleolin, and mutant Ras","volume":"71","author":"K Farin","year":"2011","journal-title":"Cancer Res"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.yexmp.2009.01.004","article-title":"Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer","volume":"86","author":"PJ Bates","year":"2009","journal-title":"Exp Mol Pathol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"599","DOI":"10.4161\/cbt.306","article-title":"Ras family signaling: therapeutic targeting","volume":"1","author":"AD Cox","year":"2002","journal-title":"Cancer Biol Ther"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0076-6879(07)00432-6","article-title":"The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer","volume":"439","author":"B Rotblat","year":"2008","journal-title":"Methods Enzymol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S1357-4310(00)01789-5","article-title":"RAS inhibitors: potential for cancer therapeutics","volume":"6","author":"Y Kloog","year":"2000","journal-title":"Mol Med Today"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1158\/1535-7163.MCT-06-0172","article-title":"Discovery and development of anticancer aptamers","volume":"5","author":"CR Ireson","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1021\/bi0119520","article-title":"Antiproliferative activity of G-quartet-forming oligonucleotides with backbone and sugar modifications. 2002","volume":"41","author":"V Dapic","year":"2002","journal-title":"Biochemistry"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"8617","DOI":"10.1158\/0008-5472.CAN-10-0920","article-title":"A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism","volume":"70","author":"EM Reyes-Reyes","year":"2010","journal-title":"Cancer Res"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0076-6879(06)06044-7","article-title":"In vitro assay of primary astrocyte migration as a tool to study Rho GTPase function in cell polarization","volume":"406","author":"S Etienne-Manneville","year":"2006","journal-title":"Methods Enzymol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"11709","DOI":"10.1158\/0008-5472.CAN-06-1878","article-title":"A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration","volume":"66","author":"L Goldberg","year":"2006","journal-title":"Cancer Res"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrclinonc.2009.111","article-title":"Implications for KRAS status and EGFR-targeted therapies in metastatic CRC","volume":"6","author":"N Normanno","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/1476-4598-9-256","article-title":"Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition","volume":"9","author":"N Charette","year":"2010","journal-title":"Mol Cancer"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/sj.onc.1201648","article-title":"Suppression of invasive properties of colon cancer cells by a metastasis suppressor KAI1 gene","volume":"16","author":"A Takaoka","year":"1998","journal-title":"Oncogene"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1349-7006.2005.00062.x","article-title":"Regulation of cancer cell motility through actin reorganization","volume":"96","author":"D Yamazaki","year":"2005","journal-title":"Cancer Sci"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1126\/science.1092053","article-title":"Cell migration: integrating signals from front to back","volume":"302","author":"AJ Ridley","year":"2003","journal-title":"Science"},{"key":"ref42","first-page":"77","article-title":"The ErbB family of receptor tyrosine kinases:key regulators in breast cancer and other malignancies","year":"2009"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0075269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T12:10:03Z","timestamp":1589026203000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0075269"}},"subtitle":[],"editor":[{"given":"Irina\u00a0V","family":"Lebedeva","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2013,9,24]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2013,9,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0075269","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,24]]}}}